Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
February 01, 2019 06:45 ET
|
Loxo Oncology, Inc.
INDIANAPOLIS and STAMFORD, CT, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration...
Lilly Announces Agreement To Acquire Loxo Oncology
January 07, 2019 06:30 ET
|
Loxo Oncology, Inc.; Eli Lilly and Company
Acquisition will broaden the scope of Lilly’s oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients...
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
December 21, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for...
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
November 26, 2018 19:16 ET
|
Loxo Oncology, Inc.
First treatment with a tumor-agnostic indication at the time of initial FDA approval75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across...
Loxo Oncology Reports Third Quarter 2018 Financial Results
November 08, 2018 06:45 ET
|
Loxo Oncology, Inc.
Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 LOXO-292 Registrational Data Expected in 2019 LOXO-292 NDA Submission Expected in Late 2019 Enrollment of First Patient in...
Loxo Oncology to Participate in Upcoming Investor Conferences
November 06, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology to Announce Third Quarter 2018 Financial Results
November 01, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress
October 21, 2018 05:12 ET
|
Loxo Oncology, Inc.
- Median Duration of Response Not Reached With One Year of Additional Follow-up - - 67 Newly Reported TRK Fusion Patients Exhibit 81% ORR - STAMFORD, Conn., Oct. 21, 2018 (GLOBE NEWSWIRE) -- Loxo...
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
October 15, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...
Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress
October 09, 2018 06:45 ET
|
Loxo Oncology, Inc.
STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers,...